San Francisco, CA  |  October 12-13, 2016

Precision Medicine 2.0: Evolving Partnerships, Ongoing Lab Hurdles and Developing Infrastructure

Featured Speakers


CHAIR: Felix W. Frueh, Ph.D., Executive Partner, Opus Three LLC

Stuart Hwang, Ph.D.
, Managing Partner, Mavericks Capital
Peter Hoehn, JD, Global Business Leader, Janssen Diagnostics

Nicholas Schork, Ph.D., Professor & Director, Human Biology, J. Craig Venter Institute

pmphoto.jpg pmphotoa.jpg quinnetal.jpg

Latest Blog Post

Media Partners

GenomeWeb is an independent online news organization that provides in-depth coverage of the scientific and economic ecosystem spurred by high-throughput genome sequencing. We are the leading information source for scientists, executives, and clinicians who use and develop advanced life science tools.

AllSeq has created the world's first true Sequencing Marketplace. You can submit your project to the Marketplace to receive competitive bids. Our online forms help guide you to create an accurate description of your sequencing project, ensuring that you receive accurate, consistent bids. Or you can browse our comprehensive list of service providers, filtering them by platform, application and specialty. Our NGS Knowledge Bank, a neutral source of information on the various sequencing technologies, platforms and applications, can help guide your project design. Our NGS Conference list includes over 100 sequencing and genomics conferences annually, many with free discount codes.

About the Conference

One of the longest running conferences in the personalized/precision medicine space, Arrowhead's 8th Annual Personalized & Precision Medicine Conference is once again returning to the San Francisco Bay Area, on October 12th-13th. With the renewed focus on precision medicine stemming from President Obama’s 2015 initiative and multiple advances in the field on a variety of fronts, this year’s conference promises to expand your thinking and put you front and center to hear from key players and stakeholders in the field.
Eight years ago Arrowhead’s Personalized & Precision Medicine Conference focused almost exclusively on the one-on-one relationship between the pharmaceutical and diagnostic industries. Since then the field has evolved to encompass not just these bilateral relationships, but multi-stakeholder, precompetitive consortia between the industries that demonstrate their continued commitment to precision medicine and the novel ways in which they are approaching the space. This year's conference will continue to examine the components that are integral to driving precision medicine into the future, including:
▶ Optimizing Coding and Reimbursement
▶ Laboratory Developed Test (LDT) Regulation
▶ Data Privacy
▶ Innovative Partnerships Furthering Precision Medicine
▶ Crowd Sourcing Therapies
▶ Truly Individualizing Therapy
▶ Ethical/social/legal issues
▶ Transforming data into actionable guidance in the clinic
▶ Weighing clinical utility
▶ Personalized medicine at the bedside
▶ Payor evaluation of next gen sequencing
▶ Aligning labs, clinicians and payers
▶ Development of genomic medicine programs
Why Attend?
PRESENTATIONS from Physicians, Researchers, Reimbursement Experts, Payers and Leaders from the Molecular Diagnostics, Biopharmaceutical and Genome Interpretation Industries
Extended Q&A SESSIONS with Speakers
PANEL DISCUSSIONS covering a variety of topics of interest to stakeholders in personalized medicine
Numerous NETWORKING OPPORTUNITIES aided by Arrowhead's pre-conference online networking suite

Networking Opportunities

You will have multiple chances to network and meet with others in the field of personalized medicine during the conference. There will be an online networking tool available before the conference even begins!
Attendees will have the opportunity to meet other attendees through the following networking services:
► Our CONFERENCE NETWORKING SITE is online weeks prior to the event. Attendees can schedule one-on-one meetings prior to the conference and print out a schedule of meeting times during the conference.
► EXTENDED NETWORKING BREAKS. These will give attendees the chance to meet those with whom they many not have set up meetings.
► EVENING RECEPTION. This will give attendees the chance to mingle with other professionals after a day full of speakers, meetings, and thought-provoking topics.
► SPEAKER Q&A SESSIONS. This will afford attendees the opportunity to ask additional questions of our speakers.

Share on Social Media

  • email
  • facebook
  • linkedin
  • twitter
  • google+
  • pinterest

Download Brochure

Speaking Opportunities

Sponsor/Exhibit Opportunities

Join Conference Mailing List

The Personalized/Precision Medicine Blog

The official blog of the Annual Personalized and Precision Medicine Conference provides readers with information, insight and analysis regarding the field of personalized and precision medicine, genomics, genomic interpretation and the evolution of healthcare in the post-genomic era.
Font size: +

Novartis, Pfizer and Thermo Fisher to Lead Panel Discussion on Developing a Universal Test NGS-Based Companion Diagnostic Designed to Support Multiple Drug Development Programs

In 2015, Novartis, Pfizer and Thermo Fisher Scientific announced a long-term partnership, with the hopes of accelerating the development and registration of several new non-small cell lung cancer (NSCLC) drugs. Over the past year, this collaboration has worked on developing and commercializing a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for NSCLC across multiple drug platforms. 
Executives from Novartis, Thermo Fisher and Pfizer will be leading a panel discussion at the 8th Annual Personalized and Precision Medicine Conference, taking place October 12-13, 2016 in San Francisco, CA.  For more information on the conference, visit: 
The three executives that will lead this panel discussion are:
Mark Stevenson, MBA, Executive VP and President of Life Science Solutions, Thermo Fisher
Anne-Marie Martin, Ph.D., Senior VP, Global Head of Precision Medicine, Novartis
Hakan Sakul, Ph.D., VP and Head of Diagnostics, Pfizer
As there is a growing demand for targeted therapies to replace the “one-size-fits-all” paradigm, stakeholders in the health care industry are looking to satisfy the ultimate goal of providing more personalized therapies and timely access to the appropriate clinical trials. With the continued use of next-generation sequencing, which allows for multiple genes to be simultaneously tested from a single sample, personalized and precision medicine are on the forefront of revolutionizing the health care industry.
The NGS-based companion diagnostic test for NSCLC is being developed using Thermo Fisher’s Ion PGM Dx System and Oncomine assays. Hakan Sakul commented on the collaboration, “the Thermo Fisher Scientific NGS panel is aligned with a number of our clinical development programs, providing us with an opportunity to accelerate the development of each of these potential therapies for NSCLC patients with targetable genetic alterations.”
Mark Stevenson of Thermo Fisher also commented that, “the potential to generate a paradigm shift through this agreement – from one test for one drug, to one test for multiple NSCLC therapies, represents a significant step forward in realizing the promise of precision medicine.” For more information on the collaboration, visit:
Rate this blog entry:
Syapse Founder Jonathan Hirsch to Present a New Vi...

Related Posts

    Testimonials from Past Conferences

    Being new to Pharmacogenomics and genetic testing, the conference was very informative. Definitely a learning experience.

    Karla S. Muller, </strong>Billing Specialist<strong>, Frontier Toxicology

    Karla S. Muller, Billing Specialist, Frontier Toxicology

    Very valuable focused sessions that provide actionable content.

    Michael Giske, Epic Sciences

    Michael Giske, Epic Sciences

    An excellent and valuable conference.

    Michelle Chen, President, Rayner-Chen Advisory

    Michelle Chen, President, Rayner-Chen Advisory

    This was my first PPMC and I was absolutely pleased with it. It was an amazing opportunity to network with other companies that are breaking into the healthcare industry, create partnerships and share challenges and hardships and try to find a way around them.

    Shelley Herek, Director of Sales, LifeMap Sciences

    Shelley Herek, Director of Sales, LifeMap Sciences

    An excellent conference that concentrates on the benefits and risks associated with the use of genetic information to provide personalized diagnostics and therapeutic options to the patient. Great coverage of social, practical and regulatory issues.

    Glenn Braunstein, MD, Chief Medical Officer, Pathway Genomics

    Glenn Braunstein, MD, Chief Medical Officer, Pathway Genomics

    Best multiple perspective insider's view of what's involved in implementing precision medicine that I've encountered thus far.

    Lee Watkins, Jr., Director of Bioinformatics and IT, Johns Hopkins University Institute of Genomic Medicine

    Lee Watkins, Jr., Director of Bioinformatics and IT, Johns Hopkins University Institute of Genomic Medicine

    Very well organized, relevant and extremely useful conference.

    Igor Keselman, Chief Operating Officer, Quremedy

    Igor Keselman, Chief Operating Officer, Quremedy

    Speakers provided a lot of deep domain expertise in diagnostics, oncology, regulatory, and patents related to personalized medicine.

    Gitte Pedersen, Chief Executive Officer, Genomic Expression

    Gitte Pedersen, Chief Executive Officer, Genomic Expression

    Who Attends

    20/20 GeneSystems, Inc. | 55th Parallel, LLC | Abbott Molecular | Abraxis Bioscience | ActX | Affymetrix, Inc. | Agendia, Inc | AlliedPath, Inc. | Almac Diagnostics | Alpha Genomix | Amgen | AncestryDNA | Appistry | Apple Tree Partners | Applied Biosystems | Arsenal Capital Partners | AssureRx Health, Inc. | AstraZeneca Pharamceuticals | Asuragen | Athena Diagnostics | Atlantic Health | Aureon Laboratories | Axial Biotech | BCBST | BCM Technologies | BD Becton Dickinson | Berkeley HeartLab, Inc. | Bio-X Center, China Fudan University | BIOCRATES Life Sciences | Biodesix, Inc. | BioM GmbH BioMarker Strategies | bioMerieux, Inc. | BioNano Genomics, Inc. | Biostat Solutions | BioTrove Inc. | BNA | Boston Biomedical Consultants | Boston Cancer Policy Institute, Inc | Boston Healthcare Associates | Brigham and Women's Hospital | Bristol Myers Squibb | BSG Institute | Cancer Care Ontario | Cedar Associates, LLC | Cedars-Sinai Medical Center | Celera Diagnostics | Chamberlain Medical Enterprises, Inc | Charite Berlin | CHU Sainte-Justine Chulalongkorn University | CIRANO | Clemson | Cleveland Clinic | Clinical Reference Laboratory | Coimbra Genomics | Consultant Core Principle Solutions | Coriell Institute for Medical Research | Covington & Burling | Crescendo Bioscience | CTG | Current Partnering | Cylex Inc | Cynergene | Decatur Memorial Hospital | deCode Genetics | Deloitte Center for Health Solutions | DHCS | Diaceutics | Diamyd Medical AB | DiTherea, Inc. | DNA Direct | DNA Genotek | Duke University | Easton Associates | Eli Lilly and Company | Elsevier | Emerson College | EPEMED | Eurolab Clinik | European Commission | F. Hoffmann-La Roche | FDA | Foley and Hoag | Foley and Lardner | Forest Laboratories, Inc. | Foundation Medicine | Fox Chase Cancer Center | Frost & Sullivan | GE Heathcare | Gen-Probe Inc | GeneDX, Inc. | Genizon Biosciences | Génome Québec | Genome Web LLC | Genomic Health, Inc. | Genomic Healthcare Strategies | Gilead Sciences, Inc | GlaxoSmithKline | Google | Green Cross Reference Lab | Hackensack University Medical Center | Harvard Medical School | Health Canada | Health Discovery Corporation | Helix Health Advisors | HIAE HillCo Health | Hopital Jean Verdier | Houston Methodist Hospital Research Institute | Humana | Ibiomedtech | Ikaria Industry Canada | Interleukin Genetics | ITHW Inc. | Jackson Laboratory for Genomic Medicine | Johns Hopkins University | JWMS | Labceutics | LabCorp | Laboratorio Genesis-MANLAB | Landspitali - University of Iceland | Life Technologies | Lilly Oncology | LS Foresight Institute, Lund University | Main Line Ventures | Mass Medical Angels | Massachusetts General Hospital | Massachusetts Institute of Technology | Max Planck Innovation GmbH | Mayo Clinic | MD Anderson Cancer Center | Mead Johnson Nutrition | Medco Health Solutions, Inc | Medical College of Wisconsin | Medical Device Consultants | Medicine Professional Corp. Giampiero Bartolucci | MedImmune, LLC | MEI Molecular | Memorial Sloan Kettering Cancer Center | Merck & Co. | Metamark Genetics | Millennium Laboratories | Millennium Pharmaceuticals | MindSpec Inc. | Mission Health | MolecularMD | Morristown Medical Center | Mount Sinai Hospital | MPEG LA | Myriad Genetic Laboratories, Inc. | Myriad Genetics Inc. | National Human Genome Institute | National Institute of Standards & Technology | Nature Medicine | NCTR/FDA | NeoGenomics Laboratories | NephroGenex, Inc. | Neurosurgery / KUH NeuroCenter | New York Presbyterian - Columbia New York University | NIDDK, National Institutes of Health | Nigist Elleni Mohammed Memorial Hospital | NIH National Library of Medicine | NCBI NIH/NHGRI | Nodality | Norwegian University of Science and Technology | Ohio State University College of Medicine | Oncology Solutions, LLC | OncoMethylome Sciences | Onyx Pharmaceuticals | Ortho Clinical Diagnostics | OSI Pharmaceuticals | Pamlab, LLC | Partners Health Care Ctr for Personalized Genetic Medicine Partners Healthcare | Pearson Investment Co. | PerkinElmer Inc. | Permedx Consulting Ltd. | Pfizer | PGxHealth | PricewaterhouseCoopers | Proskauer Rose LLP | Proventys, Inc. | Qiagen Manchester | RainDance Technologies | Randox Laboratories Ltd | Redmile Group, LLC | Regeneron Pharmaceuticals, Inc. | Regis College | Roche Molecular Diagnostics Roche Palo Alto | Roche Products Ltd | Roswell Park Cancer Institute | Rowan-SOM | Saladax Biomedical Inc. | Sanford Health | sanofi-aventis | SBIR Development Center | NCI Science Translational Medicine | Scientia Advisors | Seoul National University Hospital | Seqster, Inc. | Siemens Venture Capital | Simmons and Simmons | Sinoptia | SK Telecom Social & Scientific Systems | Sterne, Kessler, Goldstein & Fox | Stony Brook University | Stradley Ronon Stevens & Young, LLP | Suez Canal University | Synergenz BioScience, Inc | Tethys Bioscience | TGen | The Critical Path Institute | The Houston Methodist Research Institiute | The Jackson Laboratory | The PROOF Centre | Therapak Corporation | Third Rock Ventures | Thunderbird School of Global Management | UCL Institute of Child Health | UnitedHealth Group | University of Chicago | University of Delaware | University of Iowa | University of Louisville | University of North Carolina | University of Pittsburgh | University of Toronto, St. Michael's Hospital | University of Virginia | Veridex | Virginia Commonwealth University | VirtualScopics Inc. | Washington Hospital Center | MedStar Health | XIFIN, Inc.

    Who Will You Meet

    • Pharmaceutical Company Leaders
    • Diagnostic Company Leaders
    • Genome Interpretation Experts
    • Genome Sequencing Pioneers
    • Biotech Leaders
    • Healthcare Providers
    • Academicians
    • Consultants
    • Government Leaders
    • Health Insurance Executives
    • Investors
    • Venture Capitalists


    MULTIPLE NETWORKING OPPORTUNITIES Before, During and After the Summit
    ACCESS To A Contact List Of Highly Targeted Personalized Medicine Leaders
    PROMOTIONAL PLACEMENT Across A Variety Of Platforms
    ATTEND Conference Presentations Side By Side With Attendees
    BUILD Brand Awareness Within a Network of Key Organziations
     For More Information, CLICK HERE

    About Us

    Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at

    Contact Us

    For general information about the conference, please contact us at:
     This email address is being protected from spambots. You need JavaScript enabled to view it.
     5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA